Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication that the market for GLP-1 drugs could likely be a lot bigger. Based on data ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

After a nurse died after just two weight-loss injections of Mounjaro - which is approved for use on the NHS - here's ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...

Results from the Phase III SURMOUNT-1 trial show strong benefit in using the dual GLP-1/GIP agonist ... Over a 176-week ...

Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...

Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

GLP-1 RA: Glucagon-like peptide-1 (GLP-1 ... [7] Exenatide extended release: A long-acting RA version of exenatide ...